PMA device
alfapump System
Sequana Medical NV · Alfapump System (SDQ, Class III) · First FDA decision Dec 20, 2024, newest Dec 20, 2024Liver disease and liver cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
13
Naming "alfapump"
MAUDE reports
15
Brand "alfapump", since 2015
PubMed studies
37
Mentioning "alfapump"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- alfapump SystemBreakthroughPMA
P230044 · Decided Dec 20, 2024 · 358 days after receipt
Device type: alfapump System (SDQ) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "alfapump", any status and sponsor, newest update first.
University Hospital, GrenobleAcademic, hospital or other
NCT03506893 · 90 participants (planned) · Start Jul 17, 2018 · Primary completion Mar 25, 2025
Device: Alphapump · For: Ascites; Paracentesis; Cirrhosis
Sites: Amiens, France; Angers, France; Besançon, France · 10 sites in all
- International Alfapump Cohort StudyActive, not recruiting
Sequana Medical N.V.Not on our public-company list
NCT04326946 · 400 participants (planned) · Start Aug 14, 2018 · Primary completion Dec 31, 2028
Device: Alfapump · For: Liver Cirrhoses; Malignant Ascites
Sites: Leipzig, Germany; Bern, Switzerland
- Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)Pivotal-lookingActive, not recruiting
Sequana Medical N.V.Not on our public-company list
NCT03973866 · 110 participants · Start Sep 16, 2019 · Primary completion Mar 30, 2024
Device: Alfapump · For: Ascites
Sites: Phoenix, Arizona; Los Angeles, California; Worcester, Massachusetts · 15 sites in all
- Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent CongestionStatus unknown
Sequana Medical N.V.Not on our public-company list
NCT04882358 · 24 participants (planned) · Start May 27, 2021 · Primary completion Aug 31, 2022
Device: ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM · For: Heart Failure; Volume Overload
Sites: Tbilisi, Georgia · 2 sites in all
Sequana Medical N.V.Not on our public-company list
NCT04116034 · 8 participants · Start Dec 26, 2019 · Primary completion Apr 15, 2021
Device: alfapump DSR system · For: Heart Failure; Congestive Heart Failure; Cardiorenal Syndrome and 3 more
Sites: Aalst, Belgium; Tbilisi, Georgia
Sequana Medical N.V.Not on our public-company list
NCT03032211 · 0 participants · Start Dec 31, 2017 · Primary completion Dec 31, 2020
Device: Alfapump · For: Heart Failure
Sites: Budapest, Hungary
- Malignant Ascites Alfapump® StudyWithdrawn
Sequana Medical N.V.Not on our public-company list
NCT04076566 · 0 participants · Start May 31, 2020 · Primary completion Dec 2021
Device: alfapump system · For: Malignant Ascites
Sites: London, United Kingdom
University of LeipzigAcademic, hospital or other
NCT02612519 · 15 participants · Start Nov 2015 · Primary completion Apr 30, 2019
Device: Alfapump; TIPS · For: Liver Cirrhosis
Sites: Aachen, Germany; Dresden, Germany; Leipzig, Germany
- Alfapump-albumin Replacement TherapyTerminated
Sequana Medical N.V.Not on our public-company list
NCT02448160 · 10 participants (planned) · Start Jan 2016 · Primary completion Dec 2017
Device: alfapump · For: Liver Cirrhosis
Sites: London, United Kingdom
Sequana Medical N.V.Not on our public-company list
NCT03200106 · 17 participants · Start Aug 1, 2017 · Primary completion Feb 28, 2018
Device: Alfapump · For: Malignant Ascites
Sites: Leipzig, Germany; Bern, Switzerland; London, United Kingdom
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "alfapump", and for the whole product code for context.
This brand
15 reports: 3 malfunction, 12 injury, 0 death
Whole product code SDQ
15 reports: 3 malfunction, 12 injury, 0 death
Newest reports for this brand
- ALFAPUMP SYSTEMInjury
3010817031-2026-00013 · Received Jul 10, 2026 · Event dated Jun 9, 2026
Device type: Alfapump System (SDQ)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- ALFAPUMP SYSTEMInjury
3010817031-2026-00014 · Received Jul 10, 2026 · Event dated Jun 10, 2026
Device type: Alfapump System (SDQ)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- ALFAPUMP SYSTEMInjury
3010817031-2026-00015 · Received Jul 10, 2026 · Event dated Jun 10, 2026
Device type: Alfapump System (SDQ)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- ALFAPUMP SYSTEMInjury
3010817031-2026-00004 · Received Jul 10, 2026 · Event dated Feb 12, 2026
Device type: Alfapump System (SDQ)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
- ALFAPUMP SYSTEMInjury
3010817031-2026-00012 · Received Jul 2, 2026 · Event dated Jun 6, 2026
Device type: Alfapump System (SDQ)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "alfapump"[tiab]. The summary above synthesizes these.
- Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment.
Ikegami T, Ishiki H, Kadono T, et al. · Ann Palliat Med · 2024Review
- Optimal management of ascites.
Rudler M, Mallet M, Sultanik P, et al. · Liver Int · 2020Review
- Consensus care recommendations for alfapump® in cirrhotic patients with refractory or recurrent ascites.
Aagaard NK, Malago M, De Gottardi A, et al. · BMC Gastroenterol · 2022Consensus Statement
- Using the Alfapump® to control ascites enabling elective umbilical hernia repair: A case report.
Sioda NA, Vargas HE, Weidknecht JL, et al. · Hernia · 2025Case Reports
- Automated low-flow ascites pump in a real-world setting: complications and outcomes.
Solbach P, Höner Zu Siederdissen C, Wellhöner F, et al. · Eur J Gastroenterol Hepatol · 2018
- Improvement in Quality of Life and Decrease in Large-Volume Paracentesis Requirements With the Automated Low-Flow Ascites Pump.
Wong F, Bendel E, Sniderman K, et al. · Liver Transpl · 2020Research Support, Non-U.S. Gov't
- Refractory Ascites and the Alfapump.
Singh J, Calderon J, Saab S · Gastro Hep Adv · 2026Review
- Editorial: alfapump-an alternative to large-volume paracentesis for patients with refractory ascites?
Macdonald S, Jalan R · Aliment Pharmacol Ther · 2018Editorial, Comment
- Alfapump® implantable device in management of refractory ascites: An update.
Weil-Verhoeven D, Di Martino V, Stirnimann G, et al. · World J Hepatol · 2022Review
- How We Approach It: Alfapump.
Vargas HE, Knuttinen MG, Coltvet LR, et al. · Am J Gastroenterol · 2026
- Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.
Bureau C, Adebayo D, Chalret de Rieu M, et al. · J Hepatol · 2017Multicenter Study, Randomized Controlled Trial
- The Effects of Alfapump on Ascites Control and Quality of Life in Patients With Cirrhosis and Recurrent or Refractory Ascites.
Wong F, Vagas HE, Reddy KR, et al. · Am J Gastroenterol · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.